After more than a decade of discussion on value-based pricing, for the first time drug manufacturers and payors are beginning to see this model as a real possibility, and life sciences companies are beginning to seek out a path forward. We interviewed a number of pharmaceutical executives responsible for making pricing and market access decisions about the possibility of change and the form it might take. Most executives believe that some kind of pricing change will happen over the next few years.
Download the PDF to read about how drug pricing model changes may affect the pharmaceutical and health care industries, and strategies in the near-term to position for the future.
Value-based pricing in the pharmaceutical industry
Replay our webcast focusing on pharmaceutical pricing models that could soon be a reality, and how you should prepare.